Neurobiol Dis. 2012 Jan 12. [Epub ahead of print], http://dx.doi.org/10.1016/j.nbd.2011.12.054,
Petr Dusek a, c, Joseph Jankovic a, Weidong Le b
a Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
b Parkinson's Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
c Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
Keywords: Iron, neurodegeneration with brain iron accumulation (NBIA), aceruloplasminemia, neuroferritinopathy, Friedreich's ataxia, Parkinson's disease, Huntington's disease, multiple system atrophy, progressive supranuclear palsy.
Thursday, January 26, 2012
A 'Disruptive Science' Ready For Commercial Development - Gene Therapy
Mary Ann Liebert, Inc./Genetic Engineering News. (2012, January 26). "A 'Disruptive Science' Ready For Commercial Development - Gene Therapy." Medical News Today.
"The time for commercial development of gene therapy has come. Patients with diseases treatable and curable with gene therapy deserve access to the technology, which has demonstrated both its effectiveness and feasibility"
"The time for commercial development of gene therapy has come. Patients with diseases treatable and curable with gene therapy deserve access to the technology, which has demonstrated both its effectiveness and feasibility"
Subscribe to:
Posts (Atom)
